Cargando…

Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy

Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck cancer; however, CRT may cause post-treatment dysphagia. Transcutaneous electrical sensory stimulation (TESS), developed in recent years for swallowing rehabilitation, is used at many medical facilities. Although TE...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamamoto, Takao, Sato, Yuki, Yumii, Kohei, Chikuie, Nobuyuki, Taruya, Takayuki, Horibe, Yuichiro, Ishino, Takashi, Ueda, Tsutomu, Takeno, Sachio, Yoshimura, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381452/
https://www.ncbi.nlm.nih.gov/pubmed/37511742
http://dx.doi.org/10.3390/jpm13071129
_version_ 1785080447340904448
author Hamamoto, Takao
Sato, Yuki
Yumii, Kohei
Chikuie, Nobuyuki
Taruya, Takayuki
Horibe, Yuichiro
Ishino, Takashi
Ueda, Tsutomu
Takeno, Sachio
Yoshimura, Kenichi
author_facet Hamamoto, Takao
Sato, Yuki
Yumii, Kohei
Chikuie, Nobuyuki
Taruya, Takayuki
Horibe, Yuichiro
Ishino, Takashi
Ueda, Tsutomu
Takeno, Sachio
Yoshimura, Kenichi
author_sort Hamamoto, Takao
collection PubMed
description Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck cancer; however, CRT may cause post-treatment dysphagia. Transcutaneous electrical sensory stimulation (TESS), developed in recent years for swallowing rehabilitation, is used at many medical facilities. Although TESS has been used for dysphagia in several fields, its safety and efficacy in patients with head and neck cancer remain to be clarified. Therefore, this study evaluated the safety of TESS in ten patients with head and neck cancers undergoing CRT. Swallowing rehabilitation intervention and TESS implementation were performed for all patients during CRT. Non-blood-toxicity adverse events (AEs), such as dermatitis and mucositis, occurred during CRT; however, the severity was less than grade 3. No patient experienced pain due to TESS. As survival time analysis using the Kaplan–Meier method for interferential current device implementation rates revealed a feasibility of 100% for up to 60 Gy and a feasibility of 78% for up to 70 Gy, TESS may be feasible until 70 Gy. This study confirmed the feasibility and safety of TESS in the head and neck region during CRT. Although the precise mechanism of TESS on dysphagia remains unclear, its continued use has great potential for improving sensory disturbance.
format Online
Article
Text
id pubmed-10381452
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103814522023-07-29 Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy Hamamoto, Takao Sato, Yuki Yumii, Kohei Chikuie, Nobuyuki Taruya, Takayuki Horibe, Yuichiro Ishino, Takashi Ueda, Tsutomu Takeno, Sachio Yoshimura, Kenichi J Pers Med Article Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck cancer; however, CRT may cause post-treatment dysphagia. Transcutaneous electrical sensory stimulation (TESS), developed in recent years for swallowing rehabilitation, is used at many medical facilities. Although TESS has been used for dysphagia in several fields, its safety and efficacy in patients with head and neck cancer remain to be clarified. Therefore, this study evaluated the safety of TESS in ten patients with head and neck cancers undergoing CRT. Swallowing rehabilitation intervention and TESS implementation were performed for all patients during CRT. Non-blood-toxicity adverse events (AEs), such as dermatitis and mucositis, occurred during CRT; however, the severity was less than grade 3. No patient experienced pain due to TESS. As survival time analysis using the Kaplan–Meier method for interferential current device implementation rates revealed a feasibility of 100% for up to 60 Gy and a feasibility of 78% for up to 70 Gy, TESS may be feasible until 70 Gy. This study confirmed the feasibility and safety of TESS in the head and neck region during CRT. Although the precise mechanism of TESS on dysphagia remains unclear, its continued use has great potential for improving sensory disturbance. MDPI 2023-07-12 /pmc/articles/PMC10381452/ /pubmed/37511742 http://dx.doi.org/10.3390/jpm13071129 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hamamoto, Takao
Sato, Yuki
Yumii, Kohei
Chikuie, Nobuyuki
Taruya, Takayuki
Horibe, Yuichiro
Ishino, Takashi
Ueda, Tsutomu
Takeno, Sachio
Yoshimura, Kenichi
Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy
title Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy
title_full Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy
title_fullStr Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy
title_full_unstemmed Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy
title_short Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy
title_sort evaluation of the safety of percutaneous sensory nerve stimulation in patients with head and neck cancer receiving chemoradiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381452/
https://www.ncbi.nlm.nih.gov/pubmed/37511742
http://dx.doi.org/10.3390/jpm13071129
work_keys_str_mv AT hamamototakao evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy
AT satoyuki evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy
AT yumiikohei evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy
AT chikuienobuyuki evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy
AT taruyatakayuki evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy
AT horibeyuichiro evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy
AT ishinotakashi evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy
AT uedatsutomu evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy
AT takenosachio evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy
AT yoshimurakenichi evaluationofthesafetyofpercutaneoussensorynervestimulationinpatientswithheadandneckcancerreceivingchemoradiotherapy